Odyssey Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
NASDAQ
Odyssey Therapeutics reported Q2 2026 financial results, showcasing positive clinical data for OD-001 and a cash runway extending into late 2028.
NASDAQ
Odyssey Therapeutics announced positive Phase 2a data for OD-001 in ulcerative colitis and reported a cash runway into late 2028 following its IPO and private placement.
NASDAQ
Odyssey Therapeutics, Inc. announced the closing of a private placement of 1,388,889 shares of common stock at $18.00 per share, concurrent with its initial public offering.